Participate in an interactive program about treating OIC in patients with advanced illness who are receiving palliative care and have had an insufficient response to laxatives and build a Virtual Sales Brochure.
During this brief 7-minute session, you’ll have the opportunity to:
- Learn more about OIC, including its mechanism of action and impact on patients with advanced illness who are receiving palliative care
- Learn clinical data on RELISTOR
Physician
Testimonials
Indication
RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR
beyond 4 months has not been studied.
Important Safety Information for RELISTOR
- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
- Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
- Use of RELISTOR has not been studied in patients with peritoneal catheters
- The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
- Safety and efficacy of RELISTOR have not been established in pediatric patients
Please see the full Prescribing Information.